A new area of stem cell therapy for Parkinson disease

Authors

  • Khaled M. Hassan Department of Medicine, Consultant Family Medicine
  • Zahra H. Alqarni Department of Medicine, King Khalid University, Saudi Arabia
  • Ali A. Almontashri Department of Medicine, King Khalid University, Saudi Arabia
  • Ahmed M. Allubly Department of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Saudi Arabia
  • Khalid A. Alalmaee Department of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Saudi Arabia
  • Fatemah A. Alhalawani Department of Medicine, King Abdulaziz University, Saudi Arabia
  • Fahad M. Alshalfan Department of Medicine, Imam Muhammad Ibn Saud Islamic University, Saudi Arabia
  • Muayad M. Anbarserri Department of Medicine, Imam Muhammad Ibn Saud Islamic University, Saudi Arabia
  • Mohammed S. Almalki Department of Medicine, Taif University, Saudi Arabia
  • Mohammed A. Tai Department of Medicine, Jeddah University, Saudi Arabia
  • Weaam A. Felemban Department of Medicine, Umm Alqura, Saudi Arabia
  • Mansoor D. Alhassani Department of Medicine, Umm Alqura, Saudi Arabia
  • Ali A. Alkhamis Department of Medicine, King Faisal University, Saudi Arabia
  • Atheer A. Alsultan Department of Medicine, King Faisal University, Saudi Arabia
  • Saud N. Almuqbil Department of Medicine, Alfarabi college of medicine, Saudi Arabia
  • Fahad S. Alsadoon Department of Medicine, Alfarabi college of medicine, Saudi Arabia

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20204402

Keywords:

Parkinson's disease, Stem cells, Pluripotent stem cells, Alpha synuclein, Animal model, Cell therapy, Dopaminergic neurons, Induced pluripotent stem cells, Neurodegeneration

Abstract

No treatment currently can be used in order to slow or even stop the progression of Parkinson's disease. Nowadays, researchers are already using stem cells to grow dopamine-producing nerve cells in the lab so that they can study the disease, especially in those cases where there is a known genetic cause for the condition. The development of the advanced cellular therapies and using induced pluripotent stem cells is making it possible to combat the progression of the disease without the resulting motor complications. It has been shown that the transplantation of many cell sources leads to reduce Parkinson’s disease symptoms in animal models.

Author Biography

Khaled M. Hassan, Department of Medicine, Consultant Family Medicine

.

References

Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson′s disease. Nat Genet. 2009;41,1303-7.

Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson′s disease. Nat Genet. 2009;41,1308-12.

Bellenguez C, Bevan S, Gschwendtner A, Spencer CC, Burgess AI, Pirinen M, et al. Dissection of the genetics of Parkinson′s disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet. 2011;20:345-53.

Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson′s disease: a clinico-pathological study. Brain. 2010;133:1755-62.

Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 287. 2000;1265-69.

Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Natur. 2000;404(6776):394-8.

Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuro. 2010;66(5): 646-61.

Larsen K, Hedegaard C, Bertelsen MF, Bendixen C. Threonine 53 in α-synuclein is conserved in long-living non-primate animals. Biochemi Biophysic Resear Communicat. 2009;387(3):602-5.

Bottomley RH, Trainer AL, Griffin MJ. Enzymatic and chromosomal characterization of HeLa variants. J Cell Biol. 1969;41(3):806-15.

Jankovic J. Parkinson?s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatr. 2008;79:368-76.

Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, et al. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nature Communications. 2011;2(1):1-0.

Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 1997;27;276(5321): 2045-7.

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature. 1997;388(6645):839-40.

Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. [alpha]-synuclein locus triplication causes Parkinson's disease. Science. 2003;302(5646):841-2.

Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Agid Y, et al. French Parkinson's Disease Genetics Study Group. Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364(9440):1169-71.

Downloads

Published

2020-10-26

How to Cite

Hassan, K. M., Alqarni, Z. H., Almontashri, A. A., Allubly, A. M., Alalmaee, K. A., Alhalawani, F. A., Alshalfan, F. M., Anbarserri, M. M., Almalki, M. S., Tai, M. A., Felemban, W. A., Alhassani, M. D., Alkhamis, A. A., Alsultan, A. A., Almuqbil, S. N., & Alsadoon, F. S. (2020). A new area of stem cell therapy for Parkinson disease. International Journal Of Community Medicine And Public Health, 7(11), 4615–4618. https://doi.org/10.18203/2394-6040.ijcmph20204402

Issue

Vol. 7 No. 11 (2020): November 2020

Section

Systematic Reviews